FDA Adverse Event Injury Summary report: N

JUVEDERM VOLBELLA XC 2 X 1ML 32G

MDR report key: 21893036 · Received April 23, 2025

Report

Report Number
3005113652-2025-00392
Event Type
Injury
Date Received
April 23, 2025
Date of Event
March 1, 2025
Report Date
April 29, 2025
Manufacturer
PRINGY
Product Code
LMH
UDI-DI
10888628043541
PMA / PMN Number
P110033
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CT, US
Reporter Occupation
117

Narratives

Additional Manufacturer Narrative · 0

CLARIFICATION TO H.6. TYPE OF INVESTIGATION CODE: THE FILLER WAS INJECTED INTO THE PATIENT AND IS NOT ACCESSIBLE FOR RETURN. THE SYRINGE WAS NOT RETURNED FOR EVALUATION. FURTHER INFORMATION REGARDING EVENT, PRODUCT, OR PATIENT DETAILS HAS BEEN REQUESTED. NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME. THE EVENT IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT. A REVIEW OF THE DEVICE HISTORY RECORD HAS BEEN INITIATED. IF ANY NEW, CHANGED OR CORRECTED INFORMATION IS NOTED, A SUPPLEMENTAL MEDWATCH WILL BE SUBMITTED. THIS IS A KNOWN POTENTIAL ADVERSE EVENT ADDRESSED IN THE PRODUCT LABELING.

Additional Manufacturer Narrative · 0

ADDITIONAL, CORRECTED, AND/OR CHANGED DATA: H6.

Description of Event or Problem · 0

HEALTHCARE PROFESSIONAL (HCP) REPORTED INJECTING A PATIENT IN THE LIPS WITH 0.4ML OF JUVÉDERM® VOLBELLA® XC. TWENTY DAYS LATER, HCP REUSED THE SYRINGE AND INJECTED THE PATIENT WITH 0.6ML OF JUVÉDERM® VOLBELLA® XC IN THE LIPS. PATIENT BEGAN TO EXPERIENCE "VERY DELAYED NODULES" ABOUT 4 OR 5 MONTHS POST INJECTION. HCP LATER REPORTED THE PATIENT WAS PRESCRIBED VALTREX 1G BID X 7 DAYS FOR PRESENCE OF [NOT DEVICE RELATED] COLD SORE AND MEDROL DOSE PACK FOR INFLAMMATION THE SAME DAY AS SYMPTOM ONSET. ELEVEN DAYS LATER HCP INJECTED THE PATIENT WITH HYALURONIDASE 50U. THREE DAYS LATER HCP INJECTED THE PATIENT WITH HYALURONIDASE 65U. SEVEN DAYS LATER, HCP INJECTED THE PATIENT WITH HYALURONIDASE 90U. PRESCRIBED THE PATIENT VALTREX 1G BID X 7 DAYS FOR THE [NOT DEVICE RELATED] COLD SORE. SEVEN DAYS LATER, HCP INJECTED THE PATIENT WITH HYALURONIDASE 100U. PATIENT AGREED TO START TAKING PREDNISONE 30 MG X 3 DAYS, 20 MG X 2 DAYS, 10 MG X 2 DAYS. PATIENT DECLINED FURTHER TREATMENT, PREFERRING TO "ALLOW [THEIR] BODY TO NATURALLY METABOLIZE". SYMPTOMS ARE ONGOING. THIS RELATES TO THE REUSE OF THE SYRINGE. THIS IS THE SAME EVENT AND THE SAME PATIENT REPORTED UNDER PATIENT IDENTIFIER (B)(6). THIS EMDR IS BEING SUBMITTED FOR THE SUSPECT PRODUCT, REUSED SYRINGE INJECTION WITH 0.6ML OF JUVÉDERM® VOLBELLA® XC IN THE LIPS

Description of Event or Problem · 0

HEALTHCARE PROFESSIONAL (HCP) REPORTED INJECTING A PATIENT IN THE LIPS WITH 0.4ML OF JUVÉDERM® VOLBELLA® XC. TWENTY DAYS LATER, HCP REUSED THE SYRINGE AND INJECTED THE PATIENT WITH 0.6ML OF JUVÉDERM® VOLBELLA® XC IN THE LIPS. PATIENT BEGAN TO EXPERIENCE "VERY DELAYED NODULES" ABOUT 4- OR 5-MONTHS POST INJECTION. HCP LATER REPORTED THE PATIENT WAS PRESCRIBED VALTREX 1G BID X 7 DAYS FOR PRESENCE OF [NOT DEVICE RELATED] COLD SORE AND MEDROL DOSE PACK FOR INFLAMMATION THE SAME DAY AS SYMPTOM ONSET. ELEVEN DAYS LATER HCP INJECTED THE PATIENT WITH HYALURONIDASE 50U. THREE DAYS LATER HCP INJECTED THE PATIENT WITH HYALURONIDASE 65U. SEVEN DAYS LATER, HCP INJECTED THE PATIENT WITH HYALURONIDASE 90U. PRESCRIBED THE PATIENT VALTREX 1G BID X 7 DAYS FOR THE [NOT DEVICE RELATED] COLD SORE. SEVEN DAYS LATER, HCP INJECTED THE PATIENT WITH HYALURONIDASE 100U. PATIENT AGREED TO START TAKING PREDNISONE 30 MG X 3 DAYS, 20 MG X 2 DAYS, 10 MG X 2 DAYS. PATIENT DECLINED FURTHER TREATMENT, PREFERRING TO "ALLOW [THEIR] BODY TO NATURALLY METABOLIZE". SYMPTOMS ARE ONGOING. THIS RELATES TO THE REUSE OF THE SYRINGE. THIS IS THE SAME EVENT AND THE SAME PATIENT REPORTED UNDER PATIENT IDENTIFIER (B)(6). THIS EMDR IS BEING SUBMITTED FOR THE SUSPECT PRODUCT, REUSED SYRINGE INJECTION WITH 0.6ML OF JUVÉDERM® VOLBELLA® XC IN THE LIPS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1257383 JUVEDERM VOLBELLA XC 2 X 1ML 32G IMPLANT, DERMAL, FOR AESTHETIC USE LMH PRINGY 1000600429 10888628043541

Patients

Seq Age Sex Outcome Treatment
1 50 YR Female Required Intervention